MK0916 in Patients With Type 2 Diabetes and Metabolic Syndrome (0916-005)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00543595|
Recruitment Status : Completed
First Posted : October 15, 2007
Last Update Posted : May 22, 2015
This study will test the safety and effectiveness of MK0916 in patients with Type 2 Diabetes Mellitus and Metabolic Syndrome.
This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus, Type 2 Metabolic Syndrome||Drug: MK0916||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||154 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Study Start Date :||August 2004|
|Actual Primary Completion Date :||May 2005|
|Actual Study Completion Date :||May 2005|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00543595
|Study Director:||Medical Monitor||Merck Sharp & Dohme Corp.|